Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CAVA Group Inc (CAVA) vs Sanofi SA (SNY) Price & Performance

CAVA Group IncTrade

Price performance (Past 24H)

Key statistics

CAVA Group Inc vs Sanofi SA — how do they compare? CAVA Group Inc trades at $67.75 (market cap $7.17B), while Sanofi SA trades at $43.25 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 14.6× CAVA Group Inc's market cap, and Sanofi SA pays a 5.56% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.

CAVASNY
Market Cap
$7.17B$104.57B
Sector
Consumer CyclicalHealth
52-Week High
$97.39$52.34
52-Week Low
$43.59$41.33
Enterprise Value
$7.32B$124.48B
Dividend Yield
5.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CAVA Group Inc

CAVA trades at $62.42, up 0.31% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $1.18B in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights anticipation for the Q2 2026 earnings report, with analysts citing strong traffic and expansion as positive catalysts.

Wall Street maintains a bullish outlook with a consensus price target of $91.00, though high valuation multiples and recent net cash outflows pose risks. The stock's investment case hinges on continued execution of its growth strategy amid competitive industry pressures.

Sanofi SA

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CAVA Group Inc

CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.

Read more on CAVA

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY